-

Hologic to Webcast Presentations at Upcoming Investor Conferences

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:

  • Raymond James' 45th Annual Institutional Investors Conference on Monday, March 4 at 8:40 a.m. Eastern Time (ET).
  • Needham Virtual Healthcare Conference on Tuesday, April 9 at 11:45 a.m. ET.

Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcasts will be available for 30 days following each event.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

SOURCE: Hologic, Inc.

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Industry:

Hologic, Inc.

NASDAQ:HOLX
Release Summary
Hologic to Webcast Presentations at Upcoming Investor Conferences
Release Versions
English
$Cashtags
$HOLX
Hashtags
#NeedhamHealthcare
#RJII2024
#RaymondJamesInstitutionalInvestors
#holx

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Social Media Profiles
Hologic Facebook
Hologic Instagram
Hologic LinkedIn
Hologic Twitter
Hologic YouTube
More News From Hologic, Inc.

More Than One in Three U.S. Women Have Skipped or Delayed a Recommended Mammogram

MARLBOROUGH, Mass.--(BUSINESS WIRE)--More Than One in Three U.S. Women Have Skipped or Delayed a Recommended Mammogram Based on a New Survey of 1,000 Women...

New Data Shows Physicians Changed Extended Endocrine Therapy Recommendations for Over 40% of Patients Following Breast Cancer Index Testing

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. and its subsidiary, Biotheranostics, Inc., today announced newly published data in JAMA Network Open showing that Breast Cancer Index® (BCI®) test results led physicians to change their extended endocrine therapy recommendations for 42% of patients. In two-thirds of those cases, physicians changed their recommendation against extending treatment.1 The findings come from a large-scale BCI Registry Study conducted across multiple institutions at...

CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. announced today that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. Cervical cancer is the fourth most common cancer in women but is largely preventable through HPV vaccination and regular screening.1 Evidence shows that organized screening and early detection reduces deaths from cervical cancer...
Back to Newsroom